Journals / Journal of Clinical Research in Pediatric Endocrinology / 2016 / Cilt: 8 - Sayı: 3

Fluoxetine-Induced Hypoglycaemia in a Patient with Congenital Hyperinsulinism on Lanreotide Therapy

Pages
347–350
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We report a 15-year-old girl with CHI who developed persistent and recurrent hypoglycaemia secondary to fluoxetine.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Alder Hey Children's Hospital, Clinic of Pediatric Endocrinology, Liverpool, United KingdomDinesh Giri, Victoria Price, Zoe Yung, Mohammed Didi, Senthil SenniappanFluoxetine-Induced Hypoglycaemia in a Patient with Congenital Hyperinsulinism on Lanreotide Therapysubjects as well as in patients with diabetes mellitus (DM).
📊
Key Findings & Data:Selective serotonin reuptake inhibitors (SSRIs), in particular fluoxetine, have been associated with hypoglycaemia, reduced awareness of hypoglycaemic episodes, and increased insulin sensitivity in patients with DM (3,4,5,6,7).
💡
Conclusion & Impact:We report a 15-year-old girl with CHI who developed persistent and recurrent hypoglycaemia secondary to fluoxetine.
🔬Design:Lab & Field Experiment
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Alder Hey Children's Hospital, Clinic of Pediatric Endocrinology, Liverpool, United KingdomDinesh Giri, Victoria Price, Zoe Yung, Mohammed Didi, Senthil SenniappanFluoxetine-Induced Hypoglycaemia in a Patient with Congenital Hyperinsulinism on Lanreotide Therapysubjects as well as in patients with diabetes mellitus (DM). Selective serotonin reuptake inhibitors (SSRIs), in particular fluoxetine, have been associated with hypoglycaemia, reduced awareness of hypoglycaemic episodes, and increased insulin sensitivity in patients with DM (3,4,5,6,7). It is well known that unrecognised and untreated hypoglycaemia can be devastating and can potentially cause neurological damage. Moreover, the hypoglycaemic episodes occurring as a side-effect of these medications can have a negative psychological impact in a chronic condition such as DM and persistent forms of CHI. It is therefore important to be aware of the potential impact of antidepressants on glycaemic control in patients with DM and CHI. Fluoxetine-induced hypoglycaemia has been reported in the literature in adult patients with DM with paucity of literature in the paediatric population. Also, to our knowledge, there are no previous published report of fluoxetine-induced hypoglycaemia in patients with CHI. We report a 15-year-old girl with CHI who developed persistent and recurrent hypoglycaemia secondary to fluoxetine.

🔖

Cite This Article

GİRİ, D., PRİCE, V., YUNG, Z., DİDİ, M., SENNİAPPAN, S. (2016). Fluoxetine-Induced Hypoglycaemia in a Patient with Congenital Hyperinsulinism on Lanreotide Therapy. Journal of Clinical Research in Pediatric Endocrinology, Cilt: 8 - Sayı: 3, 347–350. https://ajindex.com/articles/214334

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Senniappan S, Shanti B, James C, Hussain K. J Hyperinsulinaemic hypoglycaemia: genetic mechanisms, diagnosis and management. Inherit Metab Dis 2012;35:589- 601. Epub 2012 Jan 10 McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf 2006;5:157-168.
  2. Deeg MA, Lipkin EW. Hypoglycemia associated with the use of fluoxetine. West J Med 1996;164:262-263.
  3. Khoza S, Barner JC. Glucose dysregulation associated with antidepressant agents: an analysis of 17 published case reports. Int J Clin Pharm 2011;13:484-492. Epub 2011 Apr 13 Sawka AM, Burgart V, Zimmerman D. Loss of hypoglycaemia awareness in an adolescent with type 1 diabetes mellitus during treatment with fluoxetine hydrochloride. J Pediatr 2000;136:394-396.
  4. Maheux P, Ducros F, Bourque J, Garon J, Chiasson JL. Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. Int J Obes Relat Metab Disord 1997;21:97-102.
  5. Potter van Loon BJ, Radder JK, Frölich M, Krans HM, Zwinderman AH, Meinders AE. Fluoxetine increases insulin action in obese type II (non-insulin dependent) diabetic patients. Int J Obes Relat Metab Disord 1992;16(Suppl 4):55-61.
  6. Ali S, Stone MA, Peters JL, Davies MJ, Khunti K. The prevalence of co-morbid depression in adults with Type 2 diabetes: a systematic review and meta-analysis. Diabet Med 2006;23:1165-1173.
  7. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001;24:1069-1078. http://www.nhs.uk/conditions/ssris-(selective-serotonin- reuptake inhibitors)/pages/introduction.aspx http://www.drugbank.ca/drugs/DB00472 https://www.evidence.nhs.uk/formulary/bnfc/current/4- central-nervous-system/43-antidepressant-drugs/433- selective-serotonin-re-uptake-inhibitors/fluoxetine Modan-Moses D, Koren I, Mazor-Aronovitch K, Pinhas- Hamiel O, Landau H. Treatment of congenital hyperinsulinism with lanreotide acetate (Somatuline Autogel). Clin Endocrinol Metab 2011;96:2312-2317. Epub 2011 Jun 22 Sawka AM, Burgart V, Zimmerman D. Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors. Diabetes Care 2001;24:1845-1846.
  8. Cook EH Jr, Metz J, Leventhal BL,Lebovitz M, Nathan M, Semerdjian SA, Brown T, Cooper MD. Fluoxetine effects on cerebral glucose metabolism. Neuroreport 1994;5:1745-1748